OOIR: Observatory of International Research

Papers

(The H4-Index of Clinical Pharmacology & Therapeutics is 35. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-08-01 to 2026-08-01.)

Article	Citations
Issue Information	424
Return to SENDer: The Submitted Electronic Data for Nonclinical Cardiovascular Studies is Not Facilitating Transparency, Translation or Innovation	171
Exploring the Association Between Intra‐Patient Variability in Trough Concentration of Pazopanib and Clinical Outcomes in Renal Cell Carcinoma and Soft Tissue Sarcoma Patients	121
In this Issue	102
Opportunities and Challenges of Disease Progression Modeling in Drug Development – An IQ Perspective	99
	99
FDA Adverse Event Reporting System Essentials: A Reflection on Study Conception	80
Progress in Clinical Pharmacology in China: A Randomized Controlled Study to Advance Genotype‐Guided Precision Medicine	79
Reply to “Interpretation of Pharmacovigilance Disproportionality Analyses”	78
Reply to “Questioning Bayesian Inference‐Based Models for Estimating Culprit Drugs for Adverse Drug Reactions”	70
Model‐Informed Selection of the Recommended Phase 2 Dosage for Anti‐TIGIT Immunotherapy Leveraging co‐Expressed PD‐1 Inhibitor Target Engagement	69
Integrated Evidence Planning for Enhancing Patient Care: Harnessing the Power of Real‐World Evidence	68
Enhancing External Control Arm Analyses through Data Calibration and Hybrid Designs	67
Correction to: Pharmacokinetics, Pharmacodynamics, and Safety of Vadadustat in Healthy Volunteers and Patients with Chronic Kidney Disease	66
The Efficacy, Effectiveness, and Efficiency of Integrated QTc Assessment: Rationalizing Approaches to New Drug Modalities	63
Promoting Clinical Trial Diversity: A Highlight of Select US FDA Initiatives	62
Machine Learning‐Led Optimization of Combination Therapy: Confronting the Public Health Threat of Extensively Drug Resistant Gram‐Negative Bacteria	58
A Randomized Trial Comparing Standard of Care to Bayesian Warfarin Dose Individualization	54
Advances in Clinical Therapies for Huntington's Disease and the Promise of Multi‐Targeted/Functional Drugs Based on Clinicaltrials.gov	53
Frequency of Key Pharmacogenes CYP2C9 , CYP2C19 , CYP2D6	53
Nicotine Metabolite Ratio Decreases After Switching Off Efavirenz‐Based Therapy in People With HIV Who Smoke	50
Estimating Culprit Drugs for Adverse Drug Reactions Based on Bayesian Inference	49
Drug‐Induced QT Prolongation: Associations Between Risk Classifications in a Swedish Clinical Decision Support System and Clinical Outcomes	48
US Food and Drug Administration's Advancing Real‐World Evidence Program: Initial Experience	47
More Than Pharmacokinetics: Transporters in Clinical Pharmacology	46

ICH S7B In Vitro Assays Do Not Address Mechanisms of QT_C Prolongation for Peptides and Proteins – Data in Support of Not Needing Dedicated QT_C Studies	45
Using Machine Learning to Determine a Suitable Patient Population for Anakinra for the Treatment of COVID‐19 Under the Emergency Use Authorization	42
Predicting Survival in Patients with Advanced NSCLC Treated with Atezolizumab Using Pre‐ and on‐Treatment Prognostic Biomarkers	42
	42
Requirements for Phase Lag in First‐In‐Human Trials in India: Proceedings of a Panel Discussion	40
Repeated Intake of Grapefruit Juice Inhibits CYP2B6 , CYP2C9 , CYP2C19	39
Comprehensive Evaluation of OATP‐ and BCRP‐Mediated Drug–Drug Interactions of Methotrexate Using Physiologically‐Based Pharmacokinetic Modeling	39
Methodological Insights on Biomarker‐Based Patient Selection: A Review of Scientific Advice Procedures at the European Medicines Agency	37
Denosumab Offers Relatively Lower Initial Protection Against Osteoporotic Vertebral Fractures in Treatment‐Naive Patients Compared With Zoledronate	37
Building Pharmacoequity through Student and Trainee Education, Service, and Global Outreach	37
Why Pediatric CAR ‐T Therapies Still Lag Behind: Insights from Six Treatments Centrally Approved in Europe	35